ライフサイエンスコーパス: pancreas transplant

1 y-pancreas transplant, 53% received a kidney-pancreas transplant.

2 mpared with receiving neither a kidney nor a pancreas transplant.

3 ving related kidney transplant followed by a pancreas transplant.

4 safely in patients who have lost their first pancreas transplant.

5 on dialysis, and 1 had a combined kidney and pancreas transplant.

6 ch were diagnosed at 5.5 and 42 months after pancreas transplant.

7 ignificant morbidity after kidney and kidney-pancreas transplant.

8 ive recipients of seropositive kidney and/or pancreas transplants.

9 TFs remain significant after pancreas transplants.

10 15, for studies reporting the outcome of DCD pancreas transplants.

11 1518), and 11 to 33 (n = 1377) for solitary pancreas transplants.

12 nd a high rate of graft survival in solitary pancreas transplants.

13 e from the time of the kidney as well as the pancreas transplants.

14 ssociated with the increased success rate of pancreas transplants.

15 studied 240 recipients of liver, kidney, or pancreas transplants.

16 CI, 0.62-2.78; P = 0.47) between DCD and DBD pancreas transplants.

17 ecrease in the surgical risk associated with pancreas transplants.

18 e of graft failure in technically successful pancreas transplants.

19 ver, 12 single and 14 bilateral lung, and 12 pancreas transplants.

20 ansplants, and two were recipients of kidney-pancreas transplants.

21 transplants, most liver transplants, and all pancreas transplants.

22 ge in the interpretation of outcome data for pancreas transplants.

23 ecipient survival for recipients of solitary pancreas transplants.

24 ol duodenal graft biopsies in 27 consecutive pancreas transplants (10 simultaneous pancreas kidney [S

25 March 31, 2000, the authors performed 1,194 pancreas transplants (111 from living donors; 191 retran

26 ncreas-kidney transplant, 79,198 life-years; pancreas transplant, 14,903 life-years; and intestine tr

27 We performed a total 28 pancreas transplants (17 simultaneous kidney-pancreas tr

28 occurred in 41 patients with bladder-drained pancreas transplants (25 SPK, 14 pancrease after kidney

29 Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 2

30 Retrospective analysis of 509 consecutive pancreas transplants (442 simultaneous pancreas and kidn

31 Among those who were waitlisted for a kidney-pancreas transplant, 53% received a kidney-pancreas tran

32 in 441 consecutive cadaver, bladder-drained pancreas transplants (54% simultaneous pancreas and kidn

33 Of those who received a kidney-pancreas transplant, 87% patients underwent SPKT and 13%

34 a 27-year-old female who underwent cadaveric pancreas transplant 9 months after a successful live don

35 pients with enteric-drained or duct-injected pancreas transplants, a laparoscopic or open biopsy shou

36 20 pancreas transplanted alone [PTA], and 47 pancreas transplanted after kidney [PAK]), performed at

37 ter than pancreas after kidney transplant or pancreas transplant alone (11.2 vs. 2.5 years).

38 1), pancreas after kidney (PAK) (n=389), and pancreas transplant alone (PTA) (n=204).

39 7), pancreas after kidney (PAK) (n=399), and pancreas transplant alone (PTA) (n=211).

40 Solitary pancreas transplants, both pancreas transplant alone (PTA) and pancreas after kidne

41 Pancreas transplant alone (PTA) has become accepted ther

42 Recipients of a pancreas transplant alone (PTA) have varying levels of k

43 A pancreas transplant alone (PTA) in a nonuremic patient w

44 ts with end-stage renal disease, the role of pancreas transplant alone (PTA) in the therapy of T1D su

45 Pancreas transplant alone (PTA) is a controversial proce

46 Results were compared with outcomes in pancreas transplant alone (PTA) recipients reported to t

47 pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA).

48 idney (SPK), pancreas after kidney (PAK) and pancreas transplant alone (PTA).

49 as after kidney transplantation [PAK], and 6 pancreas transplant alone [PTA]) between November 2006 a

50 ease after kidney transplants [PAK], amd two pancreas transplant alone [PTA]).

51 [SPK]; 22% pancreas after kidney [PAK]; 24% pancreas transplant alone [PTA]; 37% retransplant).

52 eas-kidney (SPK) and 4308 solitary pancreas (pancreas transplant alone and pancreas after kidney) tra

53 is indication may be about to match those of pancreas transplant alone in insulin independence.

54 Pancreas transplant alone is utilized rarely in diabetic

55 ic drainage, particularly in patients with a pancreas transplant alone or a pancreas after kidney tra

56 ation in native kidneys and urinary tract of pancreas transplant alone patients is not uncommon.

57 pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5%, 1.2%, and

58 PKs over pancreas after kidney transplant or pancreas transplant alone to limit the loss of precious

59 Thirty-eight recipients of pancreas transplant alone were evaluated for evidence of

60 nt, 42% pancreas after kidney transplant, 8% pancreas transplant alone) were biopsied.

61 idence interval [CI], 0.98-2.53; P =.06) for pancreas transplant alone, 1.42 (95% CI, 1.03-1.94; P =.

62 underwent simultaneous kidney and pancreas, pancreas transplant alone, and pancreas after kidney bet

63 year survival rates were 96.5% and 85.2% for pancreas transplant alone, respectively, and 95.3% and 8

64 on the waiting list were 97.6% and 92.1% for pancreas transplant alone, respectively, and 97.1% and 8

65 reas kidney transplantation, and the third a pancreas transplant alone.

66 2 simultaneous pancreas and kidney [SPK], 20 pancreas transplanted alone [PTA], and 47 pancreas trans

67 had SPK transplants without BM, 14 (17%) had pancreas transplants alone (PTA), and 7 (9%) had pancrea

68 reas after kidney (PAK) transplants; and 291 pancreas transplants alone (PTA).

69 Only sequential kidney and pancreas or pancreas transplants alone from live donors had been don

70 pancreas-after-kidney transplants and seven pancreas transplants alone were performed without consid

71 , 13 pancreas after kidney transplants and 4 pancreas transplants alone were performed.

72 n type I patients and did not differ between pancreas transplant and control groups.

73 eatinine levels>1.5 mg/dl at the time of the pancreas transplant and recipient age<30 years.

74 of gene expression with clinical outcome of pancreas transplants and justifies further studies in an

75 kidney transplant, one a simultaneous kidney-pancreas transplant, and the third a living related kidn

76 nce, waitlisted for kidney-alone (vs. kidney-pancreas) transplant, and higher body mass index (longer

77 ategories, and outcomes of patients having a pancreas transplant are discussed, particularly with ref

78 We conclude that successful pancreas transplants are efficacious for periods as long

79 Whole and segmental pancreas transplants are now successful for up to two de

80 Pancreas transplants are rarely done in type 2 (noninsul

81 s of 1014 patients undergoing deceased donor pancreas transplant at a single center.

82 factors, and outcomes of CMV infection after pancreas transplant at our center from January 1, 1998,

83 ther a living, cadaveric, or combined kidney-pancreas transplant at our center, and four cases of all

84 (53 men, 29 women) with bladder-drained (BD) pancreas transplants, at 1 to 80 (median, 14) months aft

85 nts at our center who received kidney and/or pancreas transplants between January 2000 and April 2003

86 Data from 232 percutaneous US-guided pancreas transplant biopsies performed in 88 patients we

87 We retrospectively reviewed all laparoscopic pancreas transplant biopsies performed over a 15-month p

88 individual renal transplant biopsies and 19 pancreas transplant biopsies were assayed for expression

89 Pancreas transplant biopsies were taken within approxima

90 Laparoscopic pancreas transplant biopsy allows safe visualization of

91 pancreas-specific genes were evaluated in 26 pancreas transplant biopsy specimens by quantitative rea

92 rmed a pilot feasibility study of mRNA-based pancreas transplant biopsy stratification.

93 Solitary pancreas transplants, both pancreas transplant alone (PT

94 ne (DD KA), not because of the addition of a pancreas transplant but because of differences in organ

95 A in patients undergoing simultaneous kidney-pancreas transplant by evaluating the functional recover

96 While pancreas transplant can be complicated by early graft lo

97 lants for suitable candidates, but currently pancreas transplants can be applied and should be an opt

98 are, unless accepted for a local whole organ pancreas transplant candidate, preferentially allocated

99 rofiles in type 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate

100 ymptomatic type 1 and 2 DM kidney and kidney-pancreas transplant candidates.

101 the transplant patient registry of a kidney-pancreas transplant center between 1984 and 2012.

102 /United Network for Organ Sharing Kidney and Pancreas Transplant Committee retrospectively analyzed t

103 We hypothesized that solitary pancreas transplants could be performed successfully eve

104 the United Network for Organ Sharing kidney/pancreas transplant database investigates factors at the

105 er KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22).

106 comes of primary versus retransplant for all pancreas transplants done in our program over nearly 35

107 We genotyped 435 pancreas transplant donors and 431 recipients who had un

108 We studied the outcome of 225 solitary pancreas transplants during three immunosuppressive eras

109 US findings, are associated with subsequent pancreas transplant failure.

110 The timing of the pancreas transplant for PAK recipients does not seem to

111 diabetic complications requiring whole organ pancreas transplant for salvage.

112 Eventually, islet transplants will replace pancreas transplants for suitable candidates, but curren

113 Here, CEUS studies are extended to pancreas transplants for the first time.

114 mpatible, five HLA antigen-mismatched kidney-pancreas transplant from a 17-year-old African-American

115 ansplantation Network Registry on kidney and pancreas transplants from January 1988 to December 1996,

116 Sequential kidney and pancreas transplants from LDs have been done, but until

117 Previously, we demonstrated that pancreas transplants from the diabetes resistant BB rat

118 results improve and as isolated (PAK or PTA) pancreas transplants gain in popularity, CR will become

119 Host factors (age at pancreas transplant, gender, body weight, glomerular fil

120 subjects receiving either a kidney or kidney-pancreas transplant generally have indicated no differen

121 The mean pancreas transplant graft and patient survival rates for

122 ormation exists about the effect of dnDSA on pancreas transplant graft survival.

123 The data were compared between normal pancreas transplants, grafts undergoing rejection, and g

124 Since the 1980s, pancreas transplant has become the most effective treatm

125 al venous drainage, especially with solitary pancreas transplants, has yet to be determined.

126 Numbers of pancreas transplants have been decreasing over the past

127 Traditionally, solitary pancreas transplants have been performed using systemic

128 As of December 31, 1996, a total of 9012 pancreas transplants have been reported to the Internati

129 Compared with other abdominal transplants, pancreas transplants have historically had the highest i

130 re instances with complete thrombosis of the pancreas transplant in absence of clinical manifestation

131 slet mass comparable with whole or segmental pancreas transplants in type 1 diabetic patients can res

132 ow-risk DCD pancreases, as the number of DCD pancreas transplants increase and the threshold for reje

133 Living donor pancreas transplant is a potential treatment for diabeti

134 Pancreas transplant is most commonly performed along wit

135 ncreas after kidney transplant, in which the pancreas transplant is performed some years after renal

136 e kidney transplant before proceeding with a pancreas transplant is unclear.

137 t of isolated splenic vein thrombosis in the pancreas transplant is unknown.

138 f graft failure after technically successful pancreas transplants is rejection.

139 erature on the behavior of cystic lesions in pancreas transplants is scarce, and hence a better under

140 One approach to increase the number of pancreas transplants is to share organs between procurem

141 PALK, n=389), preemptive LDK not receiving a pancreas transplant (LDK/noP, n=289), preemptive DDK (n=

142 Living donor segmental pancreas transplants (LDSPTx) have been performed select

143 For solitary pancreas transplants, low, but not medium, center volume

144 All pancreas transplants (n=124) performed in the previous 3

145 A total of 151 pancreas transplant needle biopsy specimens from 57 pati

146 We conclude that the beneficial effect of a pancreas transplant on the prevalence and severity of hy

147 ultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney

148 ificantly higher in patients with concurrent pancreas transplants or who were hospitalized with docum

149 in donors after brain death (DBD) donors on pancreas transplant outcome.

150 of previous cardiac arrest in DBD (caDBD) on pancreas transplant outcomes.

151 useful models for reporting program-specific pancreas transplant outcomes.

152 n alone followed by a solitary cadaver-donor pancreas transplant (PAK) have been the transplant optio

153 ng donor kidney followed by a deceased donor pancreas transplant (pancreas after living donor kidney

154 were observed most commonly in kidney and/or pancreas transplant patients (26%), although they were a

155 Pancreas transplant patients are free of exogenous insul

156 ntly greater in healthy control subjects and pancreas transplant patients compared with type I subjec

157 Data from 266 pancreas transplant patients including 182 simultaneous

158 We conclude that HCV infection in kidney-pancreas transplant patients results in a significantly

159 kidney retransplants in simultaneous kidney-pancreas transplant patients who lost their first kidney

160 diagnosed (34 kidney, 14 liver, and 3 kidney-pancreas transplant patients).

161 this study of 263 heart, kidney, liver, and pancreas transplant patients, BK virus (BKV) and JC viru

162 more precisely modulate immunosuppression in pancreas transplant patients.

163 responses to hypoglycemia were normalized in pancreas transplant patients.

164 F for nonsensitized primary kidney or kidney/pancreas transplant patients.

165 nd high-dose insulin infusions were lower in pancreas-transplant patients compared with healthy subje

166 In the postabsorptive state, pancreas-transplant patients had similar plasma glucose

167 During hyperinsulinemia, pancreas-transplant patients show a normal inhibition of

168 This was a retrospective review of 345 pancreas transplants performed at a single center betwee

169 We assessed risk factors for TF in 1115 pancreas transplants performed at a single center betwee

170 ucted a retrospective analysis including 342 pancreas transplants performed at our center from 2000 t

171 uthors retrospectively analyzed all solitary pancreas transplants performed at the Mayo Clinic betwee

172 We retrospectively analyzed all cadaver pancreas transplants performed at the University of Minn

173 we reviewed the posttransplant course of all pancreas transplants performed between July 1, 2002 and

174 my, thrombosis, infections, leaks) after 580 pancreas transplants performed during a 12-year period.

175 ective, single-center analysis including all pancreas transplants performed over 9 years evaluating t

176 een problematic as there are three different pancreas transplant procedures that may have different o

177 Monitoring graft survival for pancreas transplant programs has been problematic as the

178 mpared early pancreas graft outcomes at four pancreas transplant programs within the state of Michiga

179 rehensively studied after all three types of pancreas transplant (PT) including simultaneous pancreas

180 For recipients of solitary pancreas transplants (PTA and PAK), we found no differen

181 h acute antibody-mediated rejection (AMR) in pancreas transplant (PTx) is not well defined.

182 ive recipients of seropositive kidney and/or pancreas transplants received valganciclovir prophylaxis

183 ic syndrome (TTP/HUS) developing in a kidney/pancreas transplant recipient after the initiation of tr

184 Pancreas transplant recipient obesity has been associate

185 amined hypoglycemic counterregulation in any pancreas transplant recipient of more than 6 years' dura

186 hropathy in the native kidneys of a solitary-pancreas transplant recipient.

187 of the renal allograft in a combined kidney/pancreas transplant recipient.

188 This study details 11 pancreas transplant recipients (10 combined kidney and p

189 f 88 pancreas transplants were performed; 20 pancreas transplant recipients (23%) developed grade II

190 Reports of GVHD in kidney and pancreas transplant recipients almost uniformly describe

191 Thirteen pancreas transplant recipients and matched control subje

192 ly reported cases of WNV infection in kidney/pancreas transplant recipients and the general populatio

193 rent antibody induction regimens in solitary pancreas transplant recipients and to assess the role of

194 Our findings suggest that dnDSA in pancreas transplant recipients are associated with incre

195 Solitary pancreas transplant recipients between 01/98 to 02/00 (n

196 Kidney-pancreas transplant recipients can be safely switched to

197 om normal donor kidneys of successful kidney-pancreas transplant recipients during cyclosporine (CSA)

198 5) Do successful pancreas transplant recipients evince time-dependent dec

199 transplantation remains stable in successful pancreas transplant recipients for up to 19 years after

200 prospectively screened 609 kidney or kidney-pancreas transplant recipients from January 2007 to June

201 However, outcome after pregnancy in pancreas transplant recipients has not been studied in d

202 The long-term outcome of simultaneous kidney pancreas transplant recipients is not well established.

203 oid withdrawal can be safely accomplished in pancreas transplant recipients maintained on tacrolimus-

204 ew three cases of enterocutaneous fistula in pancreas transplant recipients managed nonoperatively wi

205 Group 2A consisted of seven successful pancreas transplant recipients of 5 to 11 years' duratio

206 ains a concern in seronegative kidney and/or pancreas transplant recipients of seropositive organs de

207 Thirty-six pancreas transplant recipients received an induction pro

208 ween August 2003 and May 2006, a total of 97 pancreas transplant recipients received steroid-free mai

209 We have analyzed data from all pancreas transplant recipients reported in the Scientifi

210 The results of steroid withdrawal in pancreas transplant recipients under tacrolimus immunosu

211 ty nondiabetic kidney and 30 diabetic kidney-pancreas transplant recipients underwent 24-hr Holter mo

212 ses and symptom recognition in two groups of pancreas transplant recipients using a stepped hypoglyce

213 However, epinephrine response in pancreas transplant recipients was significantly less th

214 nal allograft rejection in kidney and kidney-pancreas transplant recipients was treated with huOKT3ga

215 creening at our center; 785 kidney or kidney-pancreas transplant recipients were included in our stud

216 A case series of 31 cadaveric pancreas transplant recipients who were insulin-independ

217 retrospective cohort analysis of 137 kidney-pancreas transplant recipients who were transplanted bet

218 We compared the outcomes of pancreas transplant recipients with body mass index (BMI

219 he two most common techniques, CB and PB, in pancreas transplant recipients with presumed rejection.

220 d follow-up biopsies of 20 kidney and kidney-pancreas transplant recipients with PVAN during a time p

221 ucose production (HGP) in 10 type I diabetic pancreas transplant recipients, 10 pair-matched healthy

222 rous rejection episodes in kidney and kidney-pancreas transplant recipients, and in comparison to mur

223 We identified 541 pancreas transplant recipients, of which 121 developed d

224 transplantation, from 20 simultaneous kidney-pancreas transplant recipients, randomized to receive ei

225 ients, five kidney transplant and two kidney-pancreas transplant recipients, were treated with the mo

226 transplantation, rarely occurs in kidney and pancreas transplant recipients.

227 ee maintenance immunosuppressive protocol in pancreas transplant recipients.

228 This drug combination was evaluated in pancreas transplant recipients.

229 e unusual cases of intestinal obstruction in pancreas transplant recipients.

230 acute rejection have become less common for pancreas transplant recipients.

231 ejection rate in high-risk kidney and kidney-pancreas transplant recipients.

232 7, both MMF and tacrolimus were given to 120 pancreas transplant recipients.

233 recipients, and 18 were combined kidney and pancreas transplant recipients.

234 In conclusion, fasting HGP is increased in pancreas transplant recipients.

235 tive viremia, from 211 kidney and 141 kidney-pancreas transplant recipients.

236 A antibody monitoring in the surveillance of pancreas transplant recipients.

237 uoia ultrasound machine were evaluated in 14 pancreas transplant recipients.

238 f fasting plasma glucose (FPG) maintained in pancreas transplant recipients?

239 5 heart-transplant recipients, 5 kidney and pancreas-transplant recipients, and 2 lung-transplant re

240 ants have been reported to the International Pancreas Transplant Registry (IPTR).

241 nts, using the database of the International Pancreas Transplant Registry.

242 Chronic pancreas transplant rejection with enteric exocrine drai

243 blished data exist to guide the treatment of pancreas transplant rejection.

244 reduced exposures to cyclosporine to prevent pancreas-transplant rejection.

245 The two solitary pancreas transplants required an operating time of 3 and

246 5.7+/-4 days and 9.5+/-8 days for kidney and pancreas transplants, respectively.

247 As short-term pancreas transplant results improve and as isolated (PAK

248 If PB fails, recipients with bladder-drained pancreas transplants should undergo CB.

249 rt an experience with 71 simultaneous kidney-pancreas transplant (SKPT) recipients receiving daclizum

250 nosuppressive regimen in simultaneous kidney-pancreas transplant (SKPT) recipients.

251 ive agents may allow simultaneous kidney and pancreas transplants (SKPT) to be performed without anti

252 ney transplant (KTx) and simultaneous kidney-pancreas transplant (SPK) recipients, and identified ris

253 tion of kidney (KTx) and simultaneous kidney-pancreas transplant (SPK) recipients.

254 ion in recipients of simultaneous kidney and pancreas transplant (SPK).

255 tom recognition was significantly greater in pancreas transplant subjects than type I patients and di

256 surgery were redefined, and new criteria for pancreas transplant surgery training were developed.

257 Recent improvement in solitary pancreas transplant survival rates has narrowed the adva

258 For isolated pancreas transplants, TF is second only to rejection as

259 d the indication for the biopsy, the type of pancreas transplant, the number of needle passes, the si

260 At 36 months, for all pancreas transplants, the rejection rate was 21% for PV

261 c patients receiving either kidney or kidney-pancreas transplants, the slopes of regression lines gen

262 For solitary pancreas transplants, this option historically provided

263 nated 54 consecutive simultaneous kidney and pancreas transplants to either SE (n = 27) or PE (n = 27

264 The magnitude of the epinephrine response in pancreas transplant type I patients did not correlate wi

265 We first built a predictive model for each pancreas transplant type, and then pooled the transplant

266 Transplant rates for all pancreas transplant types reached a low in 2011 of 34.9

267 The National Pancreas Transplant Unit (NPTU) in Sydney provides a ser

268 All UK pancreas transplant units were surveyed between 2017 and

269 All UK pancreas transplant units were surveyed between 2017-201

270 1 diabetics enrolled on the renal and renal-pancreas transplant waiting list between 10/01/88 and 06

271 The number of new candidates on the pancreas transplant waiting list has decreased steadily

272 ransplantation alone, but the benefit of the pancreas transplant was evident only in bladder-drained

273 ved kidney function and receiving a solitary pancreas transplant was significantly worse compared wit

274 hepatic insulin sensitivity in recipients of pancreas transplants, we devised a staged euglycemic hyp

275 sure undergoing their first kidney or kidney-pancreas transplant were randomized to calcium, calcium

276 y and one recipient of a combined kidney and pancreas transplant were treated at our center for WNV i

277 Living donor segmental pancreas transplants were associated with higher technic

278 Between 1994 and 2003, 937 pancreas transplants were performed at our center in the

279 y 1994 and March 1998, during which time 137 pancreas transplants were performed at our center using

280 Two thousand one hundred forty-five pancreas transplants were performed at our institution b

281 h December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution.

282 Four hundred thirty-three pancreas transplants were performed at the Oxford Transp

283 A total of 65 pancreas transplants were performed between July 1, 2002

284 A total of 914 cadaver pancreas transplants were performed in the following thr

285 Between January 2006 and December 2010, 1009 pancreas transplants were performed in the United Kingdo

286 From July 1994 to January 1999, 177 pancreas transplants were performed, 151 of which were s

287 Between October 2002 and August 2003, 20 pancreas transplants were performed.

288 A total of 88 pancreas transplants were performed; 20 pancreas transpl

289 Six hundred forty solid organ pancreas transplants were performed; 238 had some form o

290 All pancreas transplants were preserved in UW solution.

291 Three of those four pancreas transplants were subsequently lost.

292 chnical failure (TF) rates remain high after pancreas transplants; while rates have decreased over th

293 tient with renal failure receiving MMF for a pancreas transplant, who presented with signs of MMF tox

294 a cadaveric combined kidney-bladder-drained pancreas transplant with a duodenocystostomy for exocrin

295 30 SPLK procedures, coordinating the cadaver pancreas transplant with simultaneous transplantation of

296 of cases, our results suggest that solitary pancreas transplants with a poor HLA match can be perfor

297 Since August 1995, 280 pancreas transplants with enteric duct drainage were ana

298 des improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesi

299 sulin independence must be achieved--as with pancreas transplants--with a single donor.

300 US-guided biopsy of pancreas transplants yielded tissue that was adequate mo